Recent Finacing
Recent Raise
SciRhom is a Munich-based biopharmaceutical company developing iRhom2-targeting therapeutic antibodies, advancing lead candidate SR-878 from positive preclinical RA and IBD models to Phase 1–ready clinical studies in Austria.
